Figure 3.

The anti‐Toll‐like receptor 4 (TLR4) agonistic monoclonal antibody (mAb) enhances the therapeutic efficacy of anti‐PD‐1 mAb. C57BL/6N mice (n = 5 per group) were inoculated s.c. on the back with MC38‐OVA (5 × 10⁵). One day after inoculation, the mice were injected s.c. with vehicle (phosphate‐buffered saline; PBS) or the combination of ovalbumin (OVA; 100 μg) and the anti‐TLR4 mAb (3 μg), followed by i.p. injection of the anti‐PD‐1 mAb (100 μg) or vehicle on days 6 and 9. Tumour volumes are shown as means ± SEMs. Two‐way ANOVA with the Tukey post hoc test; **P < 0·01, ****P < 0·0001. Data are representative of three independent experiments.